Holen Sie sich die Stockscreener-App
22.88
1.62%
0.38
Handel nachbörslich:
22.40
-0.48
-2.10%
Definium Therapeutics Inc Aktie (DFTX) Neueste Nachrichten
Definium Therapeutics (DFTX) Short Interest & Short Float | Updated May 2026 - MarketBeat
Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit - MSN
symbol__ Stock Quote Price and Forecast - CNN
Definium Therapeutics eyes key DT-120 depression data, advances anxiety program - MSN
Definium Therapeutics Eyes Key DT-120 Depression Data, Advances Anxiety Program - TradingView
Jefferies Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $35 - Moomoo
Definium Therapeutics: High-Stakes Data Readouts Poised To Validate Best-In-Class Potential - Seeking Alpha
Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Business Wire
Definium Begins Second Phase 3 DT120 Trial As Valuation Gap Widens - Yahoo Finance
Definium Therapeutics Nears Pivotal Earnings Call Tests - The Globe and Mail
Definium Therapeutics convenes lawmakers and researchers to advance psychedelic medicine discourse - Traders Union
DFTX Stock Price, Quote & Chart | DEFINIUM THERAPEUTICS INC (NASDAQ:DFTX) - ChartMill
Definium Therapeutics Advances DT120 ODT for GAD and MDD With Promising Phase 3 Data and Billion-Dollar Market Potential - Minichart
Definium Highlights Late-Stage Psychedelic-Inspired Psychiatric Pipeline - TipRanks
Definium Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Definium posts May 2026 corporate presentation outlining Phase 3 DT120 readouts and $373.4M cash - TradingView
Definium Therapeutics (NASDAQ: DFTX) maps DT120 Phase 3 path and 2026 data - Stock Titan
Definium Therapeutics presents pre-clinical safety data on new psychedelic treatment at APA meeting - Traders Union
Definium Therapeutics (DFTX) Institutional Ownership 2026 - MarketBeat
Trump's psychedelic drug order boosts investor interest with promise of faster reviews - Reuters
Definium Therapeutics, Inc.Common Shares (NQ: DFTX - The Chronicle-Journal
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Deep Track entities disclose 3.01% stake in Definium Therapeutics (DFTX) - Stock Titan
Definium Therapeutics (DFTX) stock gains after hours: Here's what's driving the move - MSN
H.C. Wainwright Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $70 - Moomoo
Definium Therapeutics (DFTX) Is Down 6.0% After Starting Second Phase 3 DT120 Trial in MDDHas The Bull Case Changed? - Sahm
Definium Therapeutics launches pivotal Phase 3 Ascend trial in major depressive disorder - Traders Union
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
Definium Therapeutics Doses First Patient in Phase 3 Ascend Trial of DT120 ODT (LSD) for Major Depressive Disorder - Minichart
Definium Therapeutics (DFTX) Begins Phase 3 Study for Major Depr - GuruFocus
Definium doses first patient in second phase 3 depression study - Investing.com UK
Definium Therapeutics Begins Patient Dosing in Ascend Phase 3 Depression Trial - marketscreener.com
Definium begins second Phase 3 trial for DT120 - TipRanks
Definium Therapeutics says first patient dosed in Ascend study - TipRanks
Definium Therapeutics doses first patient in Phase 3 Ascend trial of DT120 ODT for MDD - TradingView
Definium Therapeutics (DFTX) doses first patient in Ascend Phase 3 DT120 depression trial - Stock Titan
DFTX.O - Reuters
Definium Therapeutics announces first patient dosed in Ascend - marketscreener.com
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder - The Joplin Globe
Definium Therapeutics engages at Fierce Biotech Week with industry communications leaders - Traders Union
Definium Therapeutics Announces New Employee Inducement Grants - Yahoo Finance
A Quick Look at Today's Ratings for Definium Therapeutics(DFTX.US), With a Forecast Between $25 to $61 - Moomoo
Definium Therapeutics, Inc. (DFTX) Price To Cash Flow - Zacks Investment Research
Analysts Offer Insights on Healthcare Companies: Alcon (ALC), Argenx Se (ARGX) and Definium Therapeutics (DFTX) - The Globe and Mail
Definium Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
Definium Therapeutics (DFTX) Deepens Losses Advancing Psychedelic Pipeline Is Its Cash Strategy Still Coherent? - Yahoo Finance
RBC Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $36 - Moomoo
DFTX Maintained by Piper Sandler -- Price Target Lowered to $48 - GuruFocus
A Quick Look at Today's Ratings for Definium Therapeutics(DFTX.US), With a Forecast Between $36 to $48 - Moomoo
DFTX SEC FilingsDefinium Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
DFTX: Definium Therapeutics Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):